French Pharmacovigilance Public System and COVID-19 Pandemic
Abstract The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:44 |
|---|---|
| Enthalten in: |
Drug safety - 44(2020), 4 vom: 28. Dez., Seite 405-408 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Grandvuillemin, Aurélie [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Anmerkungen: |
© The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2020 |
|---|
| doi: |
10.1007/s40264-020-01034-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2124602152 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2124602152 | ||
| 003 | DE-627 | ||
| 005 | 20230505091624.0 | ||
| 007 | tu | ||
| 008 | 230505s2020 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s40264-020-01034-y |2 doi | |
| 035 | |a (DE-627)OLC2124602152 | ||
| 035 | |a (DE-He213)s40264-020-01034-y-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Grandvuillemin, Aurélie |e verfasserin |0 (orcid)0000-0001-6809-6975 |4 aut | |
| 245 | 1 | 0 | |a French Pharmacovigilance Public System and COVID-19 Pandemic |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © The Author(s), under exclusive licence to Springer Nature Switzerland AG part of Springer Nature 2020 | ||
| 520 | |a Abstract The current COVID-19 pandemic is an exceptional health situation including for drug use. As there was no known effective drug for COVID-19 at the beginning of the pandemic, different candidates were proposed. In this short article, we present the French public pharmacovigilance activities during this health crisis. Although COVID-19 is a confounding factor per se, owing to its potential for multi-organ damage including the heart and kidney, the quality of the transmitted data in adverse drug reaction reports, the timeliness of feedback from clinicians, and the real-time pharmacological and medical analysis by the French network of the regional pharmacovigilance centers made it possible to swiftly identify relevant safety signals. The French National Agency of Medicine was thus able to validate the data and convey their findings very early. This decentralized organization based on medical and pharmacological evaluation of case reports has proven to be efficient and responsive in this unique and challenging healthcare emergency. | ||
| 700 | 1 | |a Drici, Milou-Daniel |4 aut | |
| 700 | 1 | |a Jonville-Bera, Annie Pierre |4 aut | |
| 700 | 1 | |a Micallef, Joelle |4 aut | |
| 700 | 1 | |a Montastruc, Jean Louis |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Drug safety |d Springer International Publishing, 1990 |g 44(2020), 4 vom: 28. Dez., Seite 405-408 |w (DE-627)130833363 |w (DE-600)1018059-X |w (DE-576)43551685X |x 0114-5916 |7 nnns |
| 773 | 1 | 8 | |g volume:44 |g year:2020 |g number:4 |g day:28 |g month:12 |g pages:405-408 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s40264-020-01034-y |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OPC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 44 |j 2020 |e 4 |b 28 |c 12 |h 405-408 | ||